Judith Pride serves as a Site Relationship Partner at Pfizer, where she plays a pivotal role in fostering robust partnerships with investigative sites. With her extensive background in compliance and a solid foundation in clinical research, Judith is the main point of contact for these...
Judith Pride serves as a Site Relationship Partner at Pfizer, where she plays a pivotal role in fostering robust partnerships with investigative sites. With her extensive background in compliance and a solid foundation in clinical research, Judith is the main point of contact for these sites, ensuring a seamless experience from site start-up to activation. Her expertise in Disease Management and Institutional Review Board (IRB) processes allows her to navigate the complexities of clinical trials effectively, ensuring that all regulatory requirements are met while maintaining the highest standards of patient care.
In her current role, Judith is accountable for building and retaining strong investigator site relationships, which are crucial for the success of Pfizer’s clinical research initiatives. She actively engages with site personnel to provide necessary support, address any issues that arise, and enhance the overall experience for investigators. Her commitment to resolving challenges quickly and efficiently not only supports the operational success of clinical trials but also reinforces Pfizer’s reputation as the “Partner of Choice” in the healthcare industry.
Judith’s leadership skills, combined with her IRB certification and hands-on experience in site management, enable her to guide teams through the intricacies of clinical research. She is particularly adept at fostering collaboration among stakeholders, ensuring that all parties are aligned and informed throughout the trial process. Her educational background, with a Master of Science in Health Sciences focused on Clinical Research Administration from George Washington University, further solidifies her capabilities in this dynamic field. Judith’s dedication to advancing clinical research and enhancing investigator relationships positions her as a key asset to Pfizer and the broader healthcare community.
